Press Releases

Press Releases

10 April 2021

Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021

Read more

08 March 2021

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

Read more

25 February 2021

Jubilant Therapeutics Announces Research Collaboration with Boston Children’s Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

Read more

05 February 2021

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors

Read more

15 January 2021

Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

Read more

07 December 2020

Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers

Read more

24 November 2020

Jubilant Therapeutics Announces Upcoming Presentation at 2020 ASH Virtual Annual Meeting

Read more

12 November 2020

Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology

Read more

04 November 2020

Jubilant Therapeutics to Participate in Upcoming Investor Conferences

Read more

20 October 2020

Jubilant Therapeutics Strengthens Scientific Advisory Board

Read more

22 June 2020

Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research, Reveals Unique Dual-Action Anti-Cancer Mechanism Underscoring First-in-Class Pipeline Asset in Hematological Tumors

Read more

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.

OK Privacy Policy